Want to see CIRX full AI Analyst Report?
Top Page
Cirtran
(OTC:CIRX)
Select Model
Select Model
Rating:40Underperform
Price Target:
$0.02
▲(0.00% Upside)
Action:Downgraded
Date:06/26/26
The score is held down primarily by weak financial quality—negative operating profitability, negative free cash flow, and deeply negative equity—alongside bearish technicals (price below key moving averages and negative MACD). The very low P/E provides some valuation support, but it is outweighed by the balance-sheet and cash-generation risks.
Positive Factors
Revenue Growth
Sustained TTM revenue growth of ~22% signals expanding end-market traction and scale potential. Over 2-6 months this revenue momentum can underpin margin recovery if fixed costs are leveraged, making it a durable driver for progressing toward stable operating profitability.
Negative Factors
Deeply Negative Equity
A ~-$22.9M equity deficit is a material structural weakness that impairs financial flexibility and increases insolvency risk. Over months this constrains access to traditional financing, can trigger creditor scrutiny or covenant issues, and elevates dilution risk if remedial capital raises are required.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
Sustained TTM revenue growth of ~22% signals expanding end-market traction and scale potential. Over 2-6 months this revenue momentum can underpin margin recovery if fixed costs are leveraged, making it a durable driver for progressing toward stable operating profitability.
Read all positive factors
Cirtran (CIRX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$104.84K
Dividend YieldN/A
Average Volume (3M)12.02K
Price to Earnings (P/E)<0.1
Beta (1Y)-1.21
Revenue Growth188.16%
EPS GrowthN/A
CountryUS
Employees4
SectorIndustrials
Sector Strength72
IndustryFood Distribution
Share Statistics
EPS (TTM)N/A
Shares Outstanding4,945,417
10 Day Avg. Volume9,745
30 Day Avg. Volume12,017
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)>-0.01
Price to Sales (P/S)0.07
P/FCF Ratio-0.16
Enterprise Value/Market Cap35.25
Enterprise Value/Revenue0.97
Enterprise Value/Gross Profit2.13
Enterprise Value/Ebitda-20.91
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Cirtran Business Overview & Revenue Model
Company Description
CirTran Corporation provides manufacturing, marketing, distribution, and technology services for consumer products, including tobacco products, medical devices, and beverages worldwide. The company manufactures, distributes, and sells condoms, ele...
How the Company Makes Money
null...
Cirtran Financial Statement Overview
Summary
Income Statement
38
Negative
Balance Sheet
14
Very Negative
Cash Flow
22
Negative
| Breakdown | Mar 2026 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 3.13M | 1.30M | 1.62M | 1.72M | 2.92M |
| Gross Profit | 1.54M | 838.64K | 1.01M | 1.02M | 1.90M |
| EBITDA | -127.92K | -1.75M | 221.70K | -562.15K | -126.73K |
| Net Income | -701.63K | -2.63M | 20.29M | -1.35M | -627.38K |
Balance Sheet | |||||
| Total Assets | 2.51M | 1.53M | 1.85M | 2.00M | 1.46M |
| Cash, Cash Equivalents and Short-Term Investments | 9.59K | 30.38K | 0.00 | 18.08K | 5.47K |
| Total Debt | 3.43M | 3.36M | 3.22M | 3.16M | 3.22M |
| Total Liabilities | 27.62M | 25.94M | 23.63M | 44.07M | 42.03M |
| Stockholders Equity | -25.11M | -24.41M | -21.78M | -42.07M | -40.56M |
Cash Flow | |||||
| Free Cash Flow | -1.34M | -46.35K | -81.02K | 159.30K | 340.66K |
| Operating Cash Flow | -1.34M | -46.35K | -72.61K | 159.30K | 344.46K |
| Investing Cash Flow | 0.00 | 15.40K | -8.41K | 0.00 | -3.80K |
| Financing Cash Flow | 1.35M | 30.95K | 62.94K | -146.69K | -443.33K |
Cirtran Risk Analysis
Cirtran disclosed 16 risk factors in its most recent earnings report. Cirtran reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Cirtran Peers Comparison
UnderperformOutperform
Sector (63)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
63 Neutral | $10.79B | 15.43 | 7.44% | 2.01% | 2.89% | -14.66% | |
56 Neutral | $151.74M | -2.14 | -27.50% | ― | -69.74% | 63.94% | |
51 Neutral | $210.57M | -3.99 | -22.42% | ― | -3.08% | -9.56% | |
51 Neutral | $510.65M | 301.59 | 0.36% | ― | 19.20% | -21.40% | |
50 Neutral | $871.98M | -3.04 | -46.27% | 20.53% | 7.52% | -1.67% | |
50 Neutral | $205.04M | 13.78 | 37.76% | ― | 9.30% | 22.99% | |
40 Underperform | $104.84K | 0.06 | ― | ― | 188.16% | ― |
* Industrials Sector Average
CIRX
Cirtran
0.02
<0.01
5.00%
CODI
Compass Diversified Holdings
11.59
5.10
78.58%
NNBR
NN
3.99
1.71
75.00%
RCMT
Rcm Technologies
28.93
3.66
14.48%
TRC
Tejon Ranch Company
18.91
1.20
6.78%
TUSK
Mammoth Energy Services
3.15
0.36
12.90%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.